Locobase® REPAIR Used as an Adjunctive to Standard Therapy in Children With Moderate to Severe Atopic Dermatitis

Inclusion Criteria: * Has given written informed consent (parents or guardian, child if applicable) * Moderate to severe AD * Continuous use of topical corticosteroid or topical calcineurin inhibitor (TCI) as active treatment of AD for more than 4 weeks prior to screening (no change in topical corticosteroid or TCI is allowed between screening and day 1) * In the opinion of the investigator, subject is unlikely to require a significant change to his/her current treatment regimen during the study period Exclusion Criteria: * Has infected lesions * The last assessment of any clinical study within 3 months prior to the expected date of entering into the study * Current use of Locobase® REPAIR * Known allergy to Locobase® REPAIR or any of its components * Any clinical condition which, in the opinion of the investigator, would not allow safe completion of the study